Crinetics Pharmaceuticals (CRNX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Key Insights
Critical company metrics and information
Share Price
$57.76Market Cap
$5.36 BillionTotal Outstanding Shares
92.74 Million SharesTotal Employees
210Dividend
No dividendIPO Date
July 18, 2018SIC Description
Pharmaceutical PreparationsHomepage
https://www.crinetics.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $20.60 Million |
Net Cash Flow From Operating Activities, Continuing | $-62.82 Million |
Net Cash Flow From Operating Activities | $-62.82 Million |
Net Cash Flow From Financing Activities, Continuing | $57.33 Million |
Net Cash Flow, Continuing | $15.11 Million |
Net Cash Flow | $15.11 Million |
Net Cash Flow From Financing Activities | $57.33 Million |
Net Cash Flow From Investing Activities, Continuing | $20.60 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations Before Tax | $-76.83 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Depreciation and Amortization | $770,000.00 |
Diluted Average Shares | $80.09 Million |
Net Income/Loss | $-76.83 Million |
Operating Income/Loss | $-87.80 Million |
Basic Average Shares | $80.09 Million |
Basic Earnings Per Share | $-0.96 |
Operating Expenses | $87.80 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-76.83 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Research and Development | $61.91 Million |
Other Operating Expenses | $25.89 Million |
Costs And Expenses | $87.80 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Nonoperating Income/Loss | $10.97 Million |
Diluted Earnings Per Share | $-0.96 |
Income/Loss From Continuing Operations After Tax | $-76.83 Million |
Net Income/Loss Attributable To Parent | $-76.83 Million |
Benefits Costs and Expenses | $0.00 |
Revenues | $0.00 |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Parent | $832.98 Million |
Liabilities And Equity | $937.37 Million |
Noncurrent Liabilities | $50.83 Million |
Accounts Payable | $4.94 Million |
Current Assets | $877.59 Million |
Other Current Liabilities | $48.62 Million |
Other Current Assets | $14.89 Million |
Equity | $832.98 Million |
Cash | $862.70 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Fixed Assets | $11.71 Million |
Other Non-current Assets | $48.08 Million |
Noncurrent Assets | $59.79 Million |
Liabilities | $104.39 Million |
Assets | $937.37 Million |
Current Liabilities | $53.56 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.